- Home
- CERO vs PMAX Comparison
CERO vs PMAX Comparison
Compare CERO & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- PMAX
- Stock Information
- Founded
- CERO 2017
- PMAX 2019
- Country
- CERO United States
- PMAX Hong Kong
- Employees
- CERO N/A
- PMAX N/A
- Industry
- CERO
- PMAX
- Sector
- CERO
- PMAX
- Exchange
- CERO Nasdaq
- PMAX Nasdaq
- Market Cap
- CERO 5.6M
- PMAX 6.7M
- IPO Year
- CERO N/A
- PMAX 2024
- Fundamental
- Price
- CERO $5.48
- PMAX $0.30
- Analyst Decision
- CERO Strong Buy
- PMAX
- Analyst Count
- CERO 2
- PMAX 0
- Target Price
- CERO $45.00
- PMAX N/A
- AVG Volume (30 Days)
- CERO 302.9K
- PMAX 2.0M
- Earning Date
- CERO 08-22-2025
- PMAX 10-17-2025
- Dividend Yield
- CERO N/A
- PMAX N/A
- EPS Growth
- CERO N/A
- PMAX N/A
- EPS
- CERO N/A
- PMAX N/A
- Revenue
- CERO N/A
- PMAX $4,694,079.00
- Revenue This Year
- CERO N/A
- PMAX N/A
- Revenue Next Year
- CERO N/A
- PMAX N/A
- P/E Ratio
- CERO N/A
- PMAX N/A
- Revenue Growth
- CERO N/A
- PMAX N/A
- 52 Week Low
- CERO $4.27
- PMAX $0.23
- 52 Week High
- CERO $895.40
- PMAX $4.60
- Technical
- Relative Strength Index (RSI)
- CERO 31.92
- PMAX 43.61
- Support Level
- CERO $4.27
- PMAX $0.23
- Resistance Level
- CERO $7.60
- PMAX $0.33
- Average True Range (ATR)
- CERO 0.54
- PMAX 0.04
- MACD
- CERO -0.22
- PMAX -0.00
- Stochastic Oscillator
- CERO 27.85
- PMAX 29.25
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.